(RTTNews) - Monday, Estrella Immunopharma (ESLA), a clinical-stage biopharmaceutical company for treating cancer and autoimmune diseases, appointed Cynthia Pussinen as the Chief Executive Officer and Board Chair, effective October 25, 2026. She succeeds Cheng Liu, who will become
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.